Micro Medical has accomplished enrolment for a US pivotal scientific examine evaluating the security and effectiveness of its MicroStent system for the remedy of infrapopliteal lesions in topics with peripheral arterial illness (PAD).
The US-headquartered firm introduced a complete of 177 sufferers have been enrolled within the randomised, managed STAND examine (NCT03477604).
The trial, led by Dr. Robert E Beasley of Palm Vascular Facilities in Miami Seaside, Florida, enrolled its remaining affected person earlier this month.
Micro Medical’s stent is being investigated by way of two cohorts within the trial. One arm can be handled with percutaneous transluminal angioplasty (PTA) – the present customary of care – along with the corporate’s stent. The opposite arm can be handled with PTA alone.
The gadget is already accepted to be used in Europe, after having acquired CE marking in February 2017.
A market model by GlobalData estimates the peripheral vascular stent market was price $1.4bn in 2022. It’s anticipated to develop globally to $3bn by 2033, with the US market anticipated to contribute $2bn.
Entry essentially the most complete Firm Profiles
in the marketplace, powered by GlobalData. Save hours of analysis. Acquire aggressive edge.
Firm Profile – free
Your obtain electronic mail will arrive shortly
We’re assured in regards to the
high quality of our Firm Profiles. Nevertheless, we wish you to take advantage of
resolution for what you are promoting, so we provide a free pattern you could obtain by
submitting the beneath type
The market’s progress is as a result of rising prevalence of PAD worldwide as populations age and sufferers residing with circumstances like diabetes, hypertension, and weight problems additionally enhance. WL Gore and Associates are present market leaders, occupying a 54.9% share of the worldwide market, based on the mannequin.
Micro Medical’s STAND trial has main endpoints of patency of goal lesion, freedom from perioperative loss of life, and freedom from main adversarial limb occasions.
Micro Medical’s scientific affairs vice-president Rita Jacob stated: We’re excited to see the info unfold to additional perceive the influence of angiosome-directed endovascular intervention and its influence on wound therapeutic, limb salvage and affected person residing independence.
“The examine’s objective has all the time been to exhibit a decrease amputation charge thereby, reducing the devastating mortality charge related to limb loss.”
Different trial milestones this 12 months within the vascular stent house embody Reflow Medical’s six-month findings from a trial investigating its gadget for the remedy of infrapopliteal arterial illness. WL Gore and Associates enrolled the first US patient in a examine investigating its vascular stent to deal with symptomatic iliofemoral venous obstruction.